Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche says Phase 2/3 trial of COVID treatment Ronapreve met its primary endpoint
01:28am, Thursday, 30'th Sep 2021
Roche Holding AG said Thursday that its Phase 2/3 trial of Covid-19 treatment Ronapreve met its primary endpoint.
Basel, 30 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospita
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
01:29pm, Friday, 24'th Sep 2021
Roche Holding AG (OTC: RHHBY) has highlighted new data for its oral spinal muscular atrophy (SMA) treatment Evrysdi, showing its benefits when given to pre-symptomatic babies with the rare disease.
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 Septembe
Basel, 22 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of three molecular PCR diagnostic test panels to simultaneously detect and differentiate common respiratory pat
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
04:11pm, Monday, 20'th Sep 2021
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests. What Happened: The Phase 3 D
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion
04:08pm, Monday, 20'th Sep 2021
Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.
New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lung Cancer
09:05am, Monday, 20'th Sep 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented new data from the Phase III IMpower010 study at the European Society
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the appro
Alzheimer's Drug for Roche Partner AC Immune Shows Promise
02:54pm, Thursday, 16'th Sep 2021
The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotec
Roche opens access to pathology imaging tools to improve patient care
01:00am, Wednesday, 15'th Sep 2021
Basel, 15 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the introduction of the Roche Digital Pathology Open Environment that allows software developers to easily integrate their
Will Roche Stock Rebound After A 7% Fall In A Week?
12:00pm, Tuesday, 14'th Sep 2021
The stock price of Roche Holding's ADR reached its all-time high of $51 in August, before a recent sell-off in the stock, which led to a 3% drop in its price in five trading days to levels of $47 curr
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
08:34am, Tuesday, 14'th Sep 2021
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezoli
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition
07:09am, Thursday, 09'th Sep 2021
Roche Holdings AG (OTC: RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021.
Basel, 09 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of the TIB Molbiol Grou
